What we do Astonea Labs Ltd manufactures and markets pharmaceuticals and cosmetics including antibiotics, multivitamins, skincare, and gynecological products in various forms like creams and tablets. |
Founded in 2,017 |
Market share Emerging player in pharma and cosmetics markets with growing domestic sales and initial exports. |
Problem solved Provides affordable, quality health and beauty products addressing chronic and everyday health issues. |
Top clients or who we serve Serves B2B contract manufacturing clients domestically and internationally alongside own B2C brand consumers under 'Glow Up' and 'Regero'. |
Key management - |
Our journey and innovations Started production in cosmetics (2019), expanded to pharmaceuticals (2021), converted to public limited and listed in 2025 via IPO raising ₹37.67 crore. |
Where we operate Primarily domestic India market with growing export footprint. |
Top products or what we offer Range includes antibiotics, antihistamines, analgesics, fungal infection drugs, skincare products under flagship brands. |
Top brands Glow Up and Regero - domestic cosmetic and pharmaceutical brands with increasing market presence. |
Raw materials needed Active pharmaceutical ingredients and cosmetic base materials. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue largely from recurring sales and contract manufacturing services. |
Our industry position Positioning as a mid-sized manufacturer with expanding market share in India and initial export markets. |
Financial highlights FY 2024-25 revenue ₹97.52 crore with ₹5.35 crore net profit, showing 31% growth over previous year. |
Geographical revenue split Domestic revenue ₹86.07 crore, exports ₹1.37 crore in FY 2024-25. |
Order book - |
Whats driving growth Increasing contract manufacturing, own brand expansion, operational efficiencies, and capital raised via IPO. |
Our future plans Expand product portfolio, scale manufacturing capacity, and increase market penetration. |
Our green promise - |
Our people and values Focused on quality workforce and compliance; diversity and inclusion details not specified. |
Key challenges ahead Market competition, raw material cost volatility, regulatory compliance post-listing. |
Interesting facts Converted from private to public limited in 2024; completed IPO and BSE SME listing in 2025. |
Risks and strategy Mitigating risks via strong governance, internal audits, and diversified product offerings. |
